1. 1 Increasing Biotech Involvement in Global Health Innovation Oxford Conference on Innovation and Technology Transfer for Global Health September 11, 2007 James A. Geraghty Genzyme Corporation

2. 2 Objectives of todays talk Provide rationale/mandate for involvement Outline possible approaches and contributions Summarize one companys involvement Catalyze discussion and new initiatives

3. 3 The Case for Corporate Involvement To maintain policy support – regulatory, pricing, IP … To maintain long-term public trust and goodwill To attract and retain highly motivated employees To develop relationships in emerging markets To develop new capabilities through partnerships Many agree – why isnt more done? Not charity- a strategic responsibility

4. 4 (Perceived) Barriers to Involvement Were not experts in these diseases We cant afford the expenses Its not in our shareholders interest Well only spark more criticism

5. 5 Twin Pillars of Partnership Access Criteria Industry Needs Guiding Principles: Maximize access: developing countries Minimize costs: prices, royalties Make IP available: PPOs, NGOs, Governments Sustainability: Offset R&D costs: funding, tax credits Provide markets: AMCs, developed world Policy support: reimbursement, IP, etc

6. 6 Potential Biotech Contributions ProductsCapabilities Some Companies All Companies

7. 7 One Companys Approach Seek out leaders in the field Focus on ways we can add value Provide IP in field to non-profit partner Retain IP rights, if any, outside field Start small and work with funders to grow

8. 8 Genzyme/DNDi Partnership: African Tryps Identify novel inhibitors of polyamine biosynthesis Genzyme Compounds impacting polyamine metabolism and other pathways Synthetic medicinal chemistry and pharmaceutical development DNDI Expertise in disease biology In vitro and in vivo testing Resources, network and infrastructure to execute clinical trials One lead has shown superior results; optimization on going

9. 9 Genzyme/Broad/MMV Partnership: Malaria Goal: Sustainable pipeline of novel clinical candidates Exploit existing drug candidates and screens Utilize new genomic database to identify novel targets Develop chemical genetics screens to validate targets Support partners in conducting clinical trials

10. 10 Conclusions Perceived barriers act as real barriers Perceptions can reflect an obsolete environment Solutions to the real problems are not easy The future belongs to those who see opportunities